Trial-by-gene · HER2-low (ERBB2)
Active clinical trials enrolling HER2-low breast cancer
Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.
HER2-low breast cancer became a treatable subgroup with DESTINY-Breast04. Active trials focus on (1) earlier-line T-DXd (DESTINY-Breast06 1L expansion), (2) HER2-ultralow (IHC 0 with membrane staining) trials extending the eligibility floor, (3) post-T-DXd resistance, and (4) ADC combination trials (T-DXd + checkpoint inhibitor, T-DXd + tucatinib).
See the HER2+ breast cheat sheet for full biology.
Browse the live listing
Search ClinicalTrials.gov for actively recruiting breast cancer trials with HER2-low or HER2-ultralow interventions.
Open ClinicalTrials.gov listingSource: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.
Representative trial phases and designs
Phase III, 1L HER2-low
DESTINY-Breast06 — T-DXd vs chemotherapy in HER2-low or HER2-ultralow HR+ mBC after endocrine therapy.
Phase II, post-T-DXd resistance
Novel HER2-targeting ADCs, sacituzumab govitecan combinations.
Phase I/II, T-DXd + ICI
T-DXd + pembrolizumab or atezolizumab in TNBC HER2-low and HR+ HER2-low.
Frequently asked questions
- Is HER2-ultralow now treatable?
- DESTINY-Breast06 included a HER2-ultralow cohort with positive efficacy signals. FDA labels may expand pending full data; the field is evolving rapidly.